6533b82cfe1ef96bd128ed07

RESEARCH PRODUCT

ERS clinical practice guidelines:high-flow nasal cannula in acute respiratory failure

Giovanni SotgiuMiguel FerrerCesare GregorettiJean-pierre FratAylin Ozsancak UgurluErgan BegumLeo M. A. HeunksJeanette BoydRaffaele ScalaLieuwe D. J. BosTeresa RendaMichelle ChatwinFederico LonghiniSimon OczkowskiLara PisaniStefano NavaWolfram WindischJoão Carlos WinckThomy ToniaArnaud W. ThillePaolo Navalesi

subject

Pulmonary and Respiratory MedicineAdultmedicine.medical_specialtymedicine.medical_treatmentmedicine.disease_causeInternal medicineOxygen therapymedicineCannulaHumansAcute respiratory failureIntensive care medicineCOPDRespiratory Distress SyndromeNoninvasive Ventilationbusiness.industryOxygen Inhalation Therapychronic respiratory failure - COPD - noinvasive ventilationmedicine.diseaseClinical PracticeOxygenPulmonologyBreathingHigh flowbusinessRespiratory InsufficiencyNasal cannula

description

BackgroundHigh-flow nasal cannula (HFNC) has become a frequently used noninvasive form of respiratory support in acute settings; however, evidence supporting its use has only recently emerged. These guidelines provide evidence-based recommendations for the use of HFNC alongside other noninvasive forms of respiratory support in adults with acute respiratory failure (ARF).Materials and methodologyThe European Respiratory Society task force panel included expert clinicians and methodologists in pulmonology and intensive care medicine. The task force used the GRADE (Grading of Recommendations, Assessment, Development and Evaluation) methods to summarise evidence and develop clinical recommendations for the use of HFNC alongside conventional oxygen therapy (COT) and noninvasive ventilation (NIV) for the management of adults in acute settings with ARF.ResultsThe task force developed eight conditional recommendations, suggesting the use of 1) HFNC over COT in hypoxaemic ARF; 2) HFNC over NIV in hypoxaemic ARF; 3) HFNC over COT during breaks from NIV; 4) either HFNC or COT in post-operative patients at low risk of pulmonary complications; 5) either HFNC or NIV in post-operative patients at high risk of pulmonary complications; 6) HFNC over COT in nonsurgical patients at low risk of extubation failure; 7) NIV over HFNC for patients at high risk of extubation failure unless there are relative or absolute contraindications to NIV; and 8) trialling NIV prior to use of HFNC in patients with COPD and hypercapnic ARF.ConclusionsHFNC is a valuable intervention in adults with ARF. These conditional recommendations can assist clinicians in choosing the most appropriate form of noninvasive respiratory support to provide to patients in different acute settings.

10.1183/13993003.01574-2021https://research.vumc.nl/en/publications/a932b336-1c16-4340-b29c-b5aa181c17f9